𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Low frequency of precore hepatitis B virus mutants in anti-hepatitis B e-positive reactivation after loss of Hepatitis B e antigen in patients with chronic Hepatitis B*1

✍ Scribed by LORIOT, M

Book ID
121998000
Publisher
John Wiley and Sons
Year
1995
Tongue
English
Weight
618 KB
Volume
21
Category
Article
ISSN
0270-9139

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Low frequency of precore hepatitis B vir
Low frequency of precore hepatitis B virus mutants in anti-hepatitis B e—positive reactivation after loss of hepatitis B e antigen in patients with chronic hepatitis B
✍ Marie Anne Loriot; Patrick Marcellin; Nathalie Talbodec; Véronique Guigonis; Mic 📂 Article 📅 1995 🏛 John Wiley and Sons 🌐 English ⚖ 611 KB

The objective of this study was to evaluate the role of hepatitis B virus (HBV) precore mutations in patients with anti-me-positive chronic hepatitis B with or without previous known HBe antigen (HBeAg) viremic phase, and to assess the potential implication of precore mutants in HBeAg-negative react

Efficacy of lamivudine in patients with
Efficacy of lamivudine in patients with hepatitis B e antigen–negative/hepatitis B virus DNA–positive (precore mutant) chronic hepatitis befficacy of lamivudine in patients with hepatitis B e antigen–negative/hepatitis B virus DNA–positive (precore mutant) chronic hepatitis befficacy of lamivudine in patients with hepatitis B e antigen–negative/hepatitis B virus DNA–positive (precore mutant) chronic hepatitis befficacy of lamivudine in patients with hepatitis B e antigen–negative/hepatitis B virus DNA–positive (precore mutant) chronic hepatitis BB
✍ Nicolaos C. Tassopoulos; Riccardo Volpes; Giuseppe Pastore; Jenny Heathcote; Mar 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 152 KB 👁 1 views

This placebo controlled, double-blind study evaluated the efficacy and safety of lamivudine in patients with hepatitis B e antigen (HBeAg)-negative/hepatitis B virus (HBV) DNA-positive chronic hepatitis B. Patients were randomized to receive 100 mg lamivudine orally once daily for 52 weeks (n ‫؍‬ 60

Dane Particle-Associated Hepatitis B e A
Dane Particle-Associated Hepatitis B e Antigen in Patients with Chronic Hepatitis B Virus Infection and Hepatitis B e Antibody
✍ Giovanni Raimondo; Serafino Recchia; Carla Lavarini; Osvaldo Crivelli; Mario Riz 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 642 KB

A commercial radioimmunoassay was adapted to detect serum Dane particle-associated HBeAg in patients whose sera contained the homologous antibody. HBeAg was released from Dane particles with guanidine HC1. Dane particles were separated from anti-HBe by gel-filtration (Sepharose 4B) and ultracentrif